In the last decade, the glucagon-like peptide-1 (GLP-1) receptor agonist (RA) drug class has revolutionized treatment for type 2 diabetes mellitus and some of its comorbidities, including obesity and cardiovascular disease. Continued advancements in the GLP-1 RA space show clinical promise for patients, though challenges-including barriers to care such as drug expense and availability-exist. This article provides an overview of available GLP-1 RAs and their mechanisms of action, indications, adverse reactions, and risks, providing practical pearls for providers along the way.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.NPR.0000000000000216 | DOI Listing |
Publication Analysis
Top Keywords
glp-1 ras
8
glp-1
4
ras newest
4
newest powerhouse
4
powerhouse metabolic
4
metabolic medicine
4
medicine decade
4
decade glucagon-like
4
glucagon-like peptide-1
4
peptide-1 glp-1
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!